Rebuilt platform delivers instant AI answers, a live connection to ChatGPT, Claude and Gemini, and full customer journey visibility; general availability begins November 2, 2026

COLUMBUS, Ohio, Nov. 3, 2026 /PRNewswire/ -- Clarivoy, the automotive industry's independent attribution and customer intelligence platform, today launched the next generation of Clarivoy, a completely rebuilt platform designed to give dealers, dealer groups, agencies and OEM partners instant, independent answers about what is driving vehicle sales. All existing Clarivoy Multi-Touch Attribution customers have now been migrated to the new platform and have full access to its new capabilities.

"Dealerships are adopting AI tools to analyze marketing performance, but many of those tools come from companies that also sell advertising. Clarivoy does not sell media, so its attribution data is independent of any channel or vendor" Steve White, CEO and Founder of Clarivoy. "The new platform adds AI analysis on top of that independent data. Automotive retail is changing how it uses data, and attribution has to change with it," said Steve White, CEO and Founder of Clarivoy. "This launch is the foundation of where Clarivoy is headed. It makes us faster, easier to work with, and it positions us to lead as dealers rely more on AI to make marketing decisions."

At the center of the launch is Claire, an AI data analyst built directly into the Clarivoy platform. Dealers can start from the reports they already use, where Claire surfaces built-in prompts that pinpoint their highest- and lowest-ROI channels and vendors, flag unusual spend, and call out month-over-month swings. Or they can simply ask a question about channels, ROAS, lead vendors, paid search, marketplaces, TV and streaming, or cost per sale. Claire returns answers within seconds, with no queries to write or prompts to engineer. Claire is included with the new Clarivoy experience at no additional cost.

The new Clarivoy MCP Connector takes those answers outside the platform. It gives a dealer's own AI tools and agents, including ChatGPT, Claude and Gemini, a secure connection to their Clarivoy data, so a dealer can ask "which lead sources drove my used truck sales last month" in whatever tool they already have open and get the answer from Clarivoy, next to anything else they have connected. No exports, no uploads, no waiting for a report. A companion API gives dealer groups, agencies and OEM partners the same access for their own reporting and BI tools.

"We rebuilt Clarivoy around one idea: answers should come to you," said Yuriy Demidko, Chief Technology and Product Officer at Clarivoy. "Claire brings those answers to life inside the platform. Our MCP Connector and API put Clarivoy's independent sales attribution inside the AI tools and systems dealers already use, so the answer shows up where the work is happening."

The next generation of Clarivoy also introduces Customer Journey Replay, which shows every touchpoint leading to a sale in a single view, filtered by make, model or year, so dealers can see what marketing is working for the specific vehicles they need to sell. A new Search Terms Report reveals the search terms behind attributed vehicle sales rather than clicks or impressions. The platform has been fully optimized for mobile with no app required, and adds a redesigned interface, near-instant load times, automated report delivery and group reporting across every rooftop in one view.

Johnson Automotive was among a select group of dealers given early access to the new platform ahead of general availability. "The Customer Journey Replay Report is my all-time favorite to show to sales managers and remind them of how much shopping activity is often happening before we ever get a chance to engage with the shopper." said Erick Kirks, Marketing Director at Johnson Automotive. "Having them at my fingertips now is golden!"

"Our customers have always been our best source of ideas, and this release reflects what they told us they want next," said Molly Kristick, CXO and CMO at Clarivoy. "As their businesses evolve, we're evolving with them. This launch builds on what they already rely on Clarivoy for and gives them even more ways to put that data to work in the tools they already use."

Dealers, dealer groups and agencies can request a demo of the next generation of Clarivoy at https://www.clarivoy.com/next-gen.

About Clarivoy

Clarivoy is the automotive industry's independent attribution and customer intelligence platform, helping dealerships, dealer groups, agencies and OEM partners understand how marketing influences the customer journey and which investments drive vehicle sales. Because Clarivoy does not sell media, it provides unbiased measurement that helps automotive organizations invest with confidence. Learn more at clarivoy.com.

Media Contact

Molly Kristick

Chief Marketing Officer

SOURCE Clarivoy

Share this article

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.

"Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer. "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade."

Key results include:

- For the third quarter, total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025.

- Product sales grew 8%, driven by volume growth.

- Seventeen products delivered at least double-digit sales growth in the third quarter.

- Seventeen products are annualizing at more than $1 billion based on third quarter sales.

- GAAP earnings per share (EPS) increased 19% from $5.93 to $7.08 for the third quarter, driven by higher revenues.

- For the third quarter, GAAP operating income increased from $2.5 billion to $3.7 billion, and GAAP operating margin increased 9.9 percentage points to 37.5%.

- Non-GAAP EPS increased 14% from $5.64 to $6.45 for the third quarter, primarily driven by higher revenues, partially offset by higher operating expenses.

- For the third quarter, non-GAAP operating income increased from $4.3 billion to $4.7 billion, and non-GAAP operating margin increased 0.2 percentage points to 47.3%.

- The Company generated $3.7 billion of free cash flow in the third quarter of 2026 versus $4.2 billion in the third quarter of 2025, driven by changes in working capital, with the third quarter of 2025 benefiting from the timing of rebates and collections, partially offset by current period business performance.

References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.

Product Sales Performance

General Medicine

- Repatha® (evolocumab) sales increased 37% year-over-year to $1,085 million in the third quarter, primarily driven by volume growth.

- EVENITY® (romosozumab-aqqg) sales increased 39% year-over-year to $751 million in the third quarter, driven by volume growth.

- Prolia® (denosumab) sales decreased 45% year-over-year to $632 million in the third quarter as multiple biosimilars have launched globally. The decrease was driven by 23% lower volume with the remainder driven equally by lower net selling price and changes to estimated sales deductions.

Rare Disease

- TEPEZZA® (teprotumumab-trbw) sales decreased 6% year-over-year to $526 million in the third quarter, driven by lower inventory levels.

- KRYSTEXXA® (pegloticase) sales increased 31% year-over-year to $419 million in the third quarter, primarily driven by higher net selling price.

- UPLIZNA® (inebilizumab-cdon) sales increased 191% year-over-year to $451 million in the third quarter, primarily driven by volume growth.

- TAVNEOS® (avacopan) sales decreased 2% year-over-year to $105 million in the third quarter, driven by 9% lower volume, 8% unfavorable changes to estimated sales deductions and 5% lower net selling price, partially offset by higher inventory levels. We continue to engage with the U.S. Food and Drug Administration (FDA) and believe that TAVNEOS demonstrates clinical effectiveness and a favorable benefit-risk profile.

Inflammation

- TEZSPIRE® (tezepelumab-ekko) sales increased 43% year-over-year to $538 million in the third quarter, driven by volume growth.

- Otezla® (apremilast) sales decreased 18% year-over-year to $481 million in the third quarter, driven by 13% lower volume, 9% unfavorable changes to estimated sales deductions and 4% lower net selling price, partially offset by higher inventory levels.

- Enbrel® (etanercept) sales increased 5% year-over-year to $611 million in the third quarter, driven by 15% favorable changes to estimated sales deductions and 8% higher inventory levels, partially offset by 14% lower net selling price, reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the Inflation Reduction Act, and lower volume.

- AMJEVITA® (adalimumab-atto)/AMGEVITA⢠(adalimumab) sales increased 24% year-over-year to $191 million in the third quarter, primarily driven by 18% volume growth and higher net selling price.

- PAVBLU® (aflibercept-ayyh) sales increased 41% year-over-year to $300 million in the third quarter, driven by 71% volume growth, partially offset by 18% lower net selling price.

Oncology

- BLINCYTO® (blinatumomab) sales increased 27% year-over-year to $496 million in the third quarter, primarily driven by volume growth.

- IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA⢠(tarlatamab) sales increased 128% year-over-year to $406 million in the third quarter, driven by volume growth.

- Vectibix® (panitumumab) sales increased 18% year-over-year to $335 million in the third quarter, primarily driven by volume growth.

- KYPROLIS® (carfilzomib) sales decreased 8% year-over-year to $330 million in the third quarter, primarily driven by lower volume.

- LUMAKRAS®/LUMYKRAS⢠(sotorasib) sales increased 6% year-over-year to $102 million in the third quarter, driven by 14% volume growth, partially offset by 5% unfavorable changes to estimated sales deductions and lower inventory levels.

- Nplate® (romiplostim) sales increased 3% year-over-year to $472 million in the third quarter. U.S. government orders were $65 million in Q3'26 compared to $90 million in Q3'25. Excluding these U.S. government orders, Nplate sales increased 11% year-over-year, primarily driven by volume growth.

- XGEVA® (denosumab) sales decreased 47% year-over-year to $288 million in the third quarter as multiple biosimilars have launched globally. The decrease was primarily driven by 32% lower volume and 11% lower net selling price.

- MVASI® (bevacizumab-awwb) sales decreased 21% year-over-year to $168 million in the third quarter, primarily driven by 11% lower net selling price and lower volume.

Established Products

- Our established products, which consist of Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), and Parsabiv® (etelcalcetide), generated $606 million of sales in the third quarter. Sales increased 14% year-over-year, driven by 19% higher net selling price, partially offset by 3% lower volume.

Product Sales Detail by Product and Geographic Region

Operating Expense, Operating Margin and Tax Rate Analysis

On a GAAP basis:

- Total Operating Expenses decreased 5% year-over-year for the third quarter. Cost of Sales as a percentage of product sales decreased 5.5 percentage points, driven by lower amortization expense from acquisition-related assets and lower manufacturing costs, partially offset by higher profit share expense and changes in our sales mix. Research & Development (R&D) expenses increased 11% driven by higher spend in Research and Early Pipeline, including business development activity. Selling, General & Administrative (SG&A) expenses decreased 2% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses. Other operating expenses for the third quarter of 2026 totaled $76 million.

- Operating Margin as a percentage of product sales increased 9.9 percentage points to 37.5%.

- Tax Rate decreased 0.5 percentage points for the third quarter primarily driven by the change in earnings mix, including lower net unrealized gains on our equity investments, partially offset by net favorable items in the prior year as compared to the current year.

On a non-GAAP basis:

- Total Operating Expenses increased 8% year-over-year for the third quarter. Cost of Sales as a percentage of product sales increased 1.1 percentage points driven by higher profit share expense and changes in our sales mix, partially offset by lower manufacturing costs. R&D expenses increased 11% driven by higher spend in Research and Early Pipeline, including business development. SG&A expenses decreased 1% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses.

- Operating Margin as a percentage of product sales increased 0.2 percentage points for the third quarter to 47.3%.

- Tax Rate decreased 2.3 percentage points for the third quarter primarily driven by the change in earnings mix.

Cash Flow and Balance Sheet

- The Company generated $3.7 billion of free cash flow in the third quarter of 2026 versus $4.2 billion in the third quarter of 2025, driven by changes in working capital, with the third quarter of 2025 benefiting from the timing of rebates and collections, partially offset by current period business performance.

- The Company declared a third quarter 2026 dividend on July 30, 2026 of $2.52 per share that was paid on September 11, 2026 to all stockholders of record as of August 21, 2026, representing a 6% increase from the same period in 2025.

- During the third quarter of 2026, there were no repurchases of shares of common stock under our stock repurchase program.

- Cash and cash equivalents totaled $13.2 billion and debt outstanding totaled $54.0 billion as of September 30, 2026.

2026 Guidance

For the full year 2026, the Company expects:

- Total revenues in the range of $38.9 billion to $39.7 billion.

- On a GAAP basis, EPS in the range of $18.34 to $19.28, and a tax rate in the range of 14.5% to 16.0%.

- On a non-GAAP basis, EPS in the range of $22.90 to $23.70, and a tax rate in the range of 15.0% to 16.5%.

- Capital expenditures to be approximately $2.6 billion.

- Share repurchases not to exceed $3.0 billion.

LEXINGTON, Ky., Nov. 3, 2026 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB, "Ramaco" or the "Company") is a leading operator and developer of high-quality, low-cost metallurgical coal in Central Appalachia and is exploring a coal, rare earth, and other critical minerals project in Wyoming. Today it reported financial results for the three and nine months ended September 30, 2026 (the "Results").

THIRD QUARTER 2026 HIGHLIGHTS

- The Company had a quarterly net loss of $(18.2) million and Class A diluted EPS of $(0.32).

- The Company had quarterly Adjusted EBITDA of $3.0 million, defined as adjusted earnings before interest, taxes, depreciation, amortization, equity-based compensation, and, when applicable, certain other non-operating and expense items that are non-recurring and not related to the underlying business performance, a non-GAAP measure ("Adjusted EBITDA"). See "Reconciliation of Non-GAAP Measures" below.

- The Company ended the third quarter with liquidity of $375 million, an increase of 38% year over year. The Company's balance sheet remains among the strongest in its history.

- The Company has successfully signed 1.7 mm tons of domestic business at an average fixed price of $139 per ton for delivery in 2027. This represents a volume increase of almost one third from 2026. When combined with 1.1 million tons of 2027 export commitments, these 2.8 million tons in sales would account for a meaningful portion of our anticipated 2027 production. Per our standard practice, we will release initial 2027 guidance after our Board of Directors meeting in early December.

- Based on year-to-date 2026 cash costs of $100 per ton, financial results from these domestic sales alone would represent over $65 million of met coal segment Adjusted EBITDA in 2027.

- During the third quarter, the Company won a favorable $30 million jury verdict against Chubb Insurance related to the 2018 Elk Creek coal storage silo failure, including $27.5 million in net economic losses and $2.5 million in additional damages. The final award amount will depend on the outcome of any post-trial motions. The Company is also entitled to an award for its attorneys' fees since this litigation commenced in 2018 in an amount that will be determined by the Court.

MARKET COMMENTARY / 2026 OUTLOOK

Rare Earths and Critical Minerals:

- Exceptional recovery results have been achieved through a series of carbochlorination tests completed at a third-party laboratory. Average recoveries were 97% for combined scandium (Sc) + gallium (Ga) + germanium (Ge), 92% for NdPr, 96% for yttrium (Y), and 97% for dysprosium (Dy) + terbium (Tb).

- The Company has received and is testing third-party e-waste samples for analytical and metallurgical evaluation. We are continuing to source additional e-waste samples to support the pre-feasibility study ("PFS") being prepared by Hatch Consultants.

- Preparation of the PFS will commence in Q1 2027 when sufficient metallurgical results are available from bench scale testing. The PFS is currently anticipated to be completed in the second half of 2027.

- The Company expects to receive an SK-1300-compliant Technical Report Summary ("TRS") for the Initial Assessment of the Brook Project in Q1 2027, which will be focused on geological matters.

- In addition to previously disclosed MOUs for potential oxide and metal purchases, the Company remains in advanced discussions regarding both potential domestic and international offtake transactions and third-party project financing involving the public and private sectors for development and construction of the critical mineral refinery.

- The pilot plant's building structure continues to be constructed in Wyoming, with completion of the building structure expected in early 2027. The interior pilot-scale processing module equipment and testing facilities are currently being engineered by Hatch, with detailed engineering and fabrication to be completed at the Zeton, Inc. facility in Ontario, Canada. Zeton has commenced front-end flowsheet design. We expect the pilot plant to be completed in the second half of 2027, subject to procurement and fabrication timelines for the modules.

Metallurgical Coal:

- As of September 30, sales commitments for 2026 totaled approximately 4.2 million tons, equal to more than 100% of 2026 production guidance at the midpoint of 3.6 million tons. Of this total, 1.3 million tons are committed to North American customers at an average realized fixed price of $137 per ton. An additional 2.1 million tons are committed to seaborne customers at an average fixed price of $110 per ton.

- In total, 3.4 million tons are committed at an average fixed price of $120 per ton. A further 0.8 million export tons are committed to seaborne customers at index-linked pricing and are not yet priced.

- U.S. low-vol and high-vol indices increased on average to $174 per ton, or 4% ($7 per ton), in the third quarter vs the second quarter of 2026. Current average spot prices are up to $191 per ton, or 9% ($17 per ton), versus the third quarter.

- As of September 30, 2026, we had approximately 900,000 tons of clean and clean equivalent coal in inventory compared to a peak of approximately 1.1 million tons during the first quarter of 2026. The September 30, 2026 inventory figure was more than 600,000 tons above normal.

- As a result of current spot prices, the Company has begun to reduce previously stockpiled inventory by selling coal into higher-priced markets. As these tons are sold and converted to cash, this should lead to a working capital liquidity benefit and reduce inventory over the next few quarters.

- Should prices hold, in the fourth quarter alone the Company anticipates levels of Adjusted EBITDA and net income could be higher than the combined amounts generated in the first three quarters of the year.

- The Company anticipates that the third section of the Berwind low vol mine and the first underground section of the Maben low vol mine will both be in production before year-end. This combined production should add 600,000 tons of additional low-vol metallurgical coal production on an annualized basis. When combined with the restart of our Laurel Fork Mine, the Company will have added almost 1 million annualized tons of low-vol production this year.

- Construction of the new rail loadout at our low-vol Maben Complex is anticipated to be completed in January 2027. This loadout is expected to reduce current trucking costs at this complex by roughly $20 per ton.

Guidance:

- The Company has refined 2026 guidance in a number of areas. On the back of continued production discipline in the high-vol market, full-year 2026 production guidance is now 3.5 â 3.6 million tons, down from 3.6 â 3.9 million tons. Full-year 2026 sales guidance is changed to 4.0 â 4.1 million tons versus 4.0 â 4.3 million tons. The Company continues to anticipate a working capital benefit in the fourth quarter.

- The Company is increasing 2026 cash cost guidance from $96 - $99 per ton to $101 - $103 per ton. This is caused by external inflationary pressures, including current diesel prices of $5.85 per gallon, compared with $2.50 per gallon at the start of the year, and U.S. rebar prices of $952 per ton, compared with $910 per ton at the start of the year.

- The Company is increasing 2026 capital expenditure guidance to $97 â $102 million from $92 - $97 million. This is reflective of the first underground section of Maben now anticipated to be running in the fourth quarter of 2026 versus the first quarter of 2027 previously.

- The Company has modestly adjusted other non-operational full-year 2026 guidance items which can be found in the guidance tables.

Fourth Quarter Class B Dividend

- The Board declared a quarterly cash dividend of $0.0742 per share on Class B common stock for the fourth quarter of 2026. The fourth quarter dividend is payable on December 18, 2026, to shareholders of record at the close of business on December 4, 2026.

MANAGEMENT COMMENTARY

Randall Atkins, Ramaco Resources' Chairman and Chief Executive Officer, commented, "As we survey the current wreckage in both the stock and capital markets over the past several weeks, we take some comfort in where we are and where we are headed.

To step back and take some perspective, we clearly feel that current stock market levels are not reflective of longer-term value. We think, however, that we are taking appropriate steps to create value for our shareholders once markets stabilize and ultimately improve, as they do in commodity-related businesses. In this environment, having a dual platform company with one existing revenue producing component while the other is in growth development mode provides us with financial stability that many in the rare earth/critical mineral space do not enjoy.

Our coal operations continue to perform well amid the difficult multi-year pricing headwinds caused by oversupply from China into global steel markets. Although our near-term costs suffer at the margins from macro impacts like higher diesel and steel prices, we still enjoy some of the lowest relative costs in the industry for our form of continuous mining. We also remain in growth mode, adding roughly 1 million tons on an annualized basis of new low vol production this year, as we shift our quality mix toward a greater level of this higher value product.

As we exited the third quarter and look ahead to 2027, we see somewhat improving markets, a meaningful start on 2027 sales at stronger pricing, and good mine cost control despite external macro pressures. This is all supported by a strong balance sheet and liquidity.

On our critical mineral platform, we are moving forward with testing of our upstream geology and development of our future separation and extraction facility. We continue to de-risk the carbochlorination processing flowsheet and have also begun testing third-party e-waste samples to enhance feedstock concentrations and ultimate oxide output.

Red Rock Resorts Announces Third Quarter 2026 Results

LAS VEGAS, Nov. 3, 2026 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ: RRR) today reported financial results for the third quarter ended September 30, 2026.

Third Quarter Results

Consolidated Operations

- Net revenues were $488.7 million for the third quarter of 2026, an increase of 2.8%, or $13.1 million, from $475.6 million in the same period of 2025.

- Net loss was $17.7 million for the third quarter of 2026, a decrease of 123.0%, or $94.6 million, from net income of $76.9 million in the same period of 2025, primarily as a result of $79.1 million in share-based compensation expense related to the Company's 50th anniversary stock awards issued in Q3 2026 and $6.9 million of one-time expenses related to the 50th anniversary.

- Adjusted EBITDA(1) was $182.6 million for the third quarter of 2026, a decrease of 4.3%, or $8.3 million, including $5.8 million of one-time expenses related to the 50th anniversary, from $190.9 million in the same period of 2025.

Las Vegas Operations

- Net revenues from Las Vegas operations were $479.1 million for the third quarter of 2026, an increase of 2.2%, or $10.5 million, from $468.6 million in the same period of 2025.

- Adjusted EBITDA from Las Vegas operations was $204.6 million for the third quarter of 2026, a decrease of 2.3%, or $4.8 million, from $209.4 million in the same period of 2025.

Native American

- Net revenues from Native American activities were $6.2 million for the third quarter of 2026, an increase of 59.0%, or $2.3 million, from $3.9 million in the same period of 2025.

- Adjusted EBITDA from Native American activities was $5.1 million for the third quarter of 2026, an increase of 30.8%, or $1.2 million, from $3.9 million in the same period of 2025.

50th Anniversary Expenses(2)

To commemorate the Company's 50th anniversary, stock awards were granted to substantially all full-time and part-time employees. As a result, the Company recognized $79.1 million of share-based compensation expense related to this grant during the quarter. In addition, the Company recognized $6.9 million of one-time expenses related to the 50th anniversary.

Balance Sheet Highlights

The Company's cash and cash equivalents at September 30, 2026 were $128.3 million and total principal amount of debt outstanding at the end of the third quarter was $3.7 billion.

Quarterly Dividend

The Company's Board of Directors has declared a cash dividend of $0.26 per Class A common share for the fourth quarter of 2026. The dividend will be payable on December 31, 2026 to all stockholders of record as of the close of business on December 15, 2026.

Prior to the payment of such dividend, Station Holdco LLC ("Station Holdco") will make a cash distribution to all unit holders of record, including the Company, of $0.26 per unit for a total distribution of approximately $29.2 million, approximately $17.3 million of which is expected to be distributed to the Company and approximately $11.9 million of which is expected to be distributed to the other unit holders of record of Station Holdco.

Conference Call Information

The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial results. The conference call will consist of prepared remarks from the Company and include a question and answer session. Those interested in participating in the call should dial (888) 317-6003, or (412) 317-6061 for international callers, approximately 15 minutes before the call start time. Please use the passcode: 6050941. A replay of the call will be available from today through November 10, 2026 at www.redrockresorts.com. A live audio webcast of the call will also be available at www.redrockresorts.com.

Presentation of Financial Information

Company Information and Forward Looking Statements

Red Rock Resorts is a holding company that owns an indirect equity interest in and manages Station Casinos LLC ("Station Casinos"). Station Casinos is the leading provider of gaming, hospitality and entertainment to the residents of Las Vegas, Nevada. Station Casinos' properties, which are located throughout the Las Vegas valley, are regional entertainment destinations and include hotels as well as various amenities, including numerous restaurants, entertainment venues, movie theaters, bowling and convention/banquet space, as well as traditional casino gaming offerings such as video poker, slot machines, table games, bingo and race and sports wagering. Station Casinos owns and operates Red Rock Casino Resort Spa, Green Valley Ranch Resort Spa Casino, Durango Resort & Casino, Palace Station Hotel & Casino, Boulder Station Hotel & Casino, Sunset Station Hotel & Casino, Santa Fe Station Hotel & Casino, Wildfire Rancho, Wildfire Boulder, Wildfire Sunset, Wildfire Valley View, Wildfire Anthem, Wildfire Lake Mead, Wildfire on Fremont and Seventy Six by Station Casinos (North Lamb, Aliante, Union Village, Tropicana, Fort Apache, Park Highlands, and Silverado Ranch). Station Casinos also owns a 50% interest in Barley's Casino & Brewing Company, Wildfire Casino & Lanes and The Greens.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, without limitation, statements regarding our expectations, hopes or intentions regarding the future. These forward-looking statements can often be identified by their use of words such as "will", "might", "predict", "continue", "forecast", "expect", "believe", "anticipate", "outlook", "could", "would", "target", "project", "intend", "plan", "seek", "estimate", "pursue", "should", "may" and "assume", or the negative thereof, as well as variations of such words and similar expressions referring to the future. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. Certain important factors, including but not limited to, financial market risks, could cause our actual results to differ materially from those expressed in our forward-looking statements. Further information on potential factors which could affect our financial condition, results of operations and business includes, without limitation, the impact of rising inflation, higher interest rates and increased energy costs on consumer demand and the Company's business, financial results and liquidity; the impact of unemployment and changes in general economic conditions on discretionary spending and consumer demand; the impact of our substantial indebtedness; the effects of local and national economic, credit and capital market conditions on consumer spending and the economy in general, and on the gaming and hotel industries in particular; the effects of competition, including locations of competitors and operating and market competition; changes in laws, including increased tax rates, regulations or accounting standards, third-party relations and approvals, and decisions of courts, regulators and governmental bodies; risks associated with construction projects, including disruption of our operations, shortages of materials or labor, unexpected costs, unforeseen permitting or regulatory issues and weather; litigation outcomes and judicial actions, including gaming legislative action, referenda and taxation; acts of war or terrorist incidents, pandemics, natural disasters or civil unrest; risks associated with the collection and retention of data about our customers, employees, suppliers and business partners; and other risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in the Company's other current and periodic reports filed from time to time with the Securities and Exchange Commission. All forward-looking statements in this document are made based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement.

View source version on http://redrockresorts.investorroom.com/:

Investors:

Stephen L. Cootey

Stephen.Cootey@redrockresorts.com

(702) 495-4214

Media:

Michael J. Britt

Michael.Britt@redrockresorts.com

(702) 495-3693

SOURCE Red Rock Resorts, Inc.

Share this article

Third quarter 2026 net revenue of $353 million

Third quarter 2026 International revenue of $59 million

Third quarter 2026 adjusted gross profit margin of 49%

Third quarter adjusted EBITDA of $78 million

STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today reported its financial and operating results for the third quarter ended September 30, 2026. All financial information is reported in accordance with U.S. generally accepted accounting principles ("U.S. GAAP" or "GAAP") and is provided in U.S. dollars unless otherwise indicated.

Chairman and CEO Boris Jordan said, "We are building the global leader in cannabis, and our third-quarter results provide further evidence that our strategy is delivering. Solid execution across the business is driving growth, strengthening our competitive position, and advancing our Built for Growth plan. Against a backdrop of increasing pressure on the consumer, cannabis demand remained resilient and our business delivered strong, broad-based growth.

Record third quarter revenue of $353 million grew 11% compared to last year, bolstered by both our domestic and international segments that grew 8% and 28%, respectively. Our U.S. business has sustained the momentum experienced in the first half of the year as this was our third consecutive quarter of domestic year-over-year growth. Adjusted gross margin was 49% and adjusted EBITDA was $78 million, representing a 22% margin. We ended the quarter with $105 million in cash on the balance sheet. Cash flow from continuing operations in the quarter was $22 million, due to timing differences that will reverse next quarter. We continue to target generating approximately $150 million in operating cash flow for the year."

Mr. Jordan continued, "These results reflect the disciplined execution of our entire team and reinforce the strength of our global platform. We are translating operational improvements into stronger financial performance, building momentum across the business, and positioning Curaleaf for sustained growth and greater cash generation."

Third Quarter 2026 Financial Highlights

- Net revenue of $352.7 million, a year-over-year increase of 10.9% compared to Q3 2025 net revenue of $317.9 million. Sequentially, net revenue increased 3.6% compared to Q2 2026 net revenue of $340.1 million

- Gross profit of $170.5 million and gross profit margin of 48.3%, a decrease of 220 basis points year-over-year

- Adjusted gross profit of $171.8 million and adjusted gross profit margin of 48.7%, a decrease of 186 basis points year-over-year

- Net loss attributable to Curaleaf Holdings, Inc. from continuing operations of $37.4 million or net loss per share from continuing operations of $0.14

- Adjusted EBITDA(1) of 77.6 million and adjusted EBITDA margin(1) of 22.0%, a 56 basis point decrease year-over-year

- Total cash and cash equivalents at quarter end totaled $104.9 million

- Repurchased 105,440 shares for a total of $1 million

Nine Months Ended September 30, 2026 Financial Highlights

- Net revenue of $1,017.0 million, a year-over-year increase of 9% compared to Q3 2025 net revenue of $935.1 million.

- Gross profit of $497.7 million and gross margin of 49%, a decrease of 248 basis points year-over-year

- Net income attributable to Curaleaf Holdings, Inc. from continuing operations of $45.2 million or net income per share from continuing operations of $0.17

- Adjusted EBITDA(1) of $211.1 million and adjusted EBITDA margin of 20.8%, a 82 basis point decrease year-over- year

- Retired and repurchased a total of 1.12 million shares for a total value of $8.4 million

Third Quarter 2026 Operational Highlights

- Expanded retail footprint in Florida to 78 with two new dispensary openings in Port Richey and Riverview bringing the nationwide footprint of operated and managed dispensaries to 188

- Relocated three dispensaries to improved retail locations in Meriden, CT, Fishtown, PA, and Boston, MA

- Added to FTSE Canada All Cap Index, the second index inclusion after the SPX/TSX index addition

- Secured the first two registrations for standardized cannabis preparations in Spain

- Commenced an Original Offer to purchase all of the issued and outstanding common shares of Aurora Cannabis Inc. for consideration consisting of SVS and cash.

Post Third Quarter 2026 Operational Highlights

- Acquired the equity interest in Boone Town Provisions, Curaleaf's fourth dispensary in New Jersey

- Expanded retail footprint in Florida to 80 with two new dispensary openings in Port Orange and Wellington bringing the nationwide footprint of operated and managed dispensaries to 191; relocated a dispensary to York, Pennsylvania

- Began receiving DEA registrations for medical marijuana dispensaries

- Enhanced the Original Offer to purchase the Aurora shares and increased the consideration. Aurora announced an alternative transaction to merge with Organigram. Curaleaf is evaluating the alternative transaction and its options for continuing to pursue an acquisition of Aurora.

Balance Sheet and Cash Flow

As of September 30, 2026, the Company had $104.9 million of cash and $636.9 million of outstanding debt, net of unamortized debt discounts and deferred financing fees.

During the nine months ended September 30, 2026, Curaleaf invested $50.0 million in capital expenditures, focused on facility upgrades, automation and selective retail expansion in strategic markets.

Shares Outstanding

The Company's basic weighted average shares outstanding was 264,882,536 and 254,941,874 for the third quarter of 2026 and 2025, respectively.

The Company's basic weighted average shares outstanding was 262,168,678 and 252,936,604 for the nine months ended September 30, 2026 and 2025, respectively.

Conference Call Information

The Company will host a conference call and audio webcast for investors and analysts on Tuesday, November 3, 2026 at 5:00 P.M. ET to discuss Q3 2026 earnings results. The call can be accessed by dialing 1-844-512-2926 in North America or internationally at 1-412-317-6300. The conference pin # is 9773371.

A replay of the conference call can be accessed at 1-855-669-9658 in North America or internationally at 1-412-317-0088, using the replay pin # 9965356.

A webcast of the call can be accessed on the investor relations section of the Curaleaf website at ir.curaleaf.com. The teleconference will be available for replay starting at approximately 7:00 P.M. ET on Tuesday, November 3, 2026 and will end at 11:59 P.M. ET on November 10, 2026.

Non-GAAP Financial and Performance Measures

Curaleaf reports its financial results in accordance with U.S. GAAP and also uses certain non-GAAP financial measures and ratios to evaluate performance. These measures, which include "adjusted gross profit," "adjusted gross profit margin," "adjusted EBITDA," "adjusted EBITDA margin," and "free cash flow from operations," do not have standardized definitions under U.S. GAAP and may not be comparable to similar measures used by other issuers.

Curaleaf defines these non-GAAP measures as follows:

- Adjusted gross profit: gross profit net of related adjustments.

- Adjusted gross profit margin: adjusted gross profit divided by total revenues, net.

- Adjusted EBITDA: income (loss) before interest, taxes, depreciation and amortization, adjusted for share-based compensation expense and other adjustments related to restructuring costs, adult use campaign and political initiatives, as well as acquisition, transaction and other non-recurring costs.

- Adjusted EBITDA margin: adjusted EBITDA divided by total revenues, net.

- Free cash flow from operations: net cash provided by operating activities from continuing operations, net of purchases and disposals of property, plant and equipment for continuing operations.

Management believes these measures (i) provide investors with additional insight into Curaleaf's financial strength and underlying performance, (ii) align external reporting with how management evaluates results and (iii) facilitate comparisons with other issuers. These measures should not be considered in isolation from, or as a substitute for, U.S. GAAP results nor should they be considered as indicators of Curaleaf's future performance. Reconciliations to the most directly comparable U.S. GAAP measures are provided in the accompanying tables.

Gross profit from continuing operations was $170.5 million in the third quarter of 2026, compared with $160.6 million in the prior-year period. On an adjusted basis, gross profit from continuing operations was $171.8 million compared with $160.8 million in the prior-year period, and adjusted gross profit margin from continuing operations was 48.7%, compared with 50.6% in the prior-year period, a decrease of 186 basis points.

Gross profit from continuing operations was $497.7 million in the nine months ended September 30, 2026, compared with $469.2 million in the prior-year period. On an adjusted basis, gross profit from continuing operations was $499.8 million, compared with $470.7 million in the prior-year period, and adjusted gross profit margin from continuing operations was 49.1%, compared with 50.3% in the prior-year period, a decrease of 123 basis points.

Adjusted EBITDA was $77.6 million for the third quarter of 2026, compared to $71.7 million for the third quarter of 2025, and Adjusted EBITDA margin decreased to 22.0%.

Adjusted EBITDA was $211.1 million in the nine months ended September 30, 2026, compared with $205.7 million in the prior-year period, and Adjusted EBITDA margin 20.8% and 21.6%, respectively.

About Curaleaf Holdings

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading global provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant.

Ten universities, three days, 29 matches and three berths at The Collegiate Cup® on the line as the Collegiate Cricket League® returns to the D.C. area

WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- The Collegiate Cricket League® (CCL), America's premier platform for collegiate cricket, announced today that it will host the 2026 Eastern Championship from Friday, Nov. 6, through Sunday, Nov. 8, at Hal & Berni Hanson Regional Park in Aldie, Virginia, near Ashburn in the Washington, D.C., area. Ten universities will compete in 29 matches across three grounds over three days, with three berths at The Collegiate Cup®, the CCL's national championship, at stake. The league invites students, alumni, families and cricket fans from across the region to attend.

The CCL is "Where the World Comes to Play College Cricket." The league brings together 50 U.S. universities and more than 750 student-athletes representing 12 nations, bringing the world's second-most-popular sport to American campuses and giving student-athletes a national stage on which to represent their schools.

With cricket returning to the Olympic Games at Los Angeles 2028, the CCL is building a development pathway for U.S.-developed talent, including the top USA Under-19 players, as well as leading cricketers from around the world. Fans at Hanson Regional Park could very likely be watching future Olympians. The field includes two members of the league's inaugural All-American class and reigning individual award winners: National Batter of the Year Omkar Zope of the University of Pittsburgh and National Bowler of the Year Aditya Josyula of Rutgers University.

The Field and Format

The 10 teams are divided into two groups of five.

- Group A: University of Pittsburgh, Virginia Tech, George Washington University, Stony Brook University and Princeton University.

- Group B: Rutgers University, Penn State, Binghamton University, Boston University and the University of Maryland.

Pittsburgh returns as the reigning regional champion after winning last year's Eastern Championship. Rutgers and George Washington also advanced from that tournament.

Each team will play four group-stage matches and one crossover match against a team from the other group. Play begins at 9 a.m. Friday and continues through Sunday afternoon across three grounds. Sunday's semifinals begin at 3 p.m., with each group winner facing the other group's runner-up. The championship final and third-place playoff follow at 5 p.m. The top three finishers advance to The Collegiate Cup®. The full schedule appears below.

All-Americans in the Field

Two members of the CCL's inaugural All-American class, reigning Batter of the Year Omkar Zope and Bowler of the Year Aditya Josyula, headline the field. Pittsburgh's Zope led the league with 698 runs last season, including a regional century off 34 balls, seven fifties and 71 sixes. Rutgers' Josyula led the league with 18 wickets, including 10 at last year's Eastern Championship, where he recorded a hat trick.

The Road to The Collegiate Cup®

The Eastern Championship's three qualifiers will join six teams that have already earned berths in Fort Lauderdale through the season's first two regional championships.

At the Western Championship, UCLA claimed the title, while Arizona State and UC San Diego also advanced. UCLA All-American batter Tanmay Desai topped the player rankings with 713 points and led all batters with 332 runs, 35 sixes and five fifties. Teammate Shiv Mathur scored the tournament's only century, with 101 runs.

At the Midwest Championship, Iowa State, Purdue and Minnesota secured the three berths. Iowa State's Param Chaudhari topped the player rankings with 402 points and led all bowlers with 13 wickets, including the tournament's only four-wicket haul. Ohio State's Satya Amman Velamarthy led all run scorers with 217 runs at an average of 72.33.

The Collegiate Cup®, the CCL's national championship, is scheduled for March 9â14, 2027, in Fort Lauderdale, Florida, with matches beginning March 10.

2026 Eastern Championship Schedule

All times Eastern. Group winners will be seeded A1 and B1; runners-up will be seeded A2 and B2.

Venue and Attendance

Hal & Berni Hanson Regional Park is a 257-acre park in Loudoun County, Virginia, located at 22831 Hanson Park Drive, Aldie, VA 20105. Spectators are welcome.

About the Collegiate Cricket League

The Collegiate Cricket League is a 501(c)(3) nonprofit organization dedicated to elevating cricket at American colleges and universities by expanding access to scholarships, varsity recognition and investment in cricket infrastructure. Its mission is to build a premier pathway for the sport's future. The Collegiate Cricket League is "Where the World Comes to Play College Cricket." To support the league's mission or help strengthen your university's cricket program as an alum, contact info@collegiatecricket.com or donate online at www.collegiatecricket.com. Donations are tax-deductible.

Follow us: Collegiate Cricket League | Facebook | Instagram

Contact: info@collegiatecricket.com

SOURCE National Cricket League (NCL) USA

Share this article

League City company becomes Southern's second location in the Houston market

LEAGUE CITY, Texas, Nov. 3, 2026 /PRNewswire/ -- Southern Home Services today announced it has acquired Vanderford Air and Plumbing of League City, Texas. The transaction closed November 2, 2026, and is Southern's second location in the Houston designated market area (DMA).

Vanderford joins Nick's Plumbing & Air Conditioning, which Southern acquired in October 2025. Together, the two companies expand Southern's capacity to serve Houston-area homeowners with heating, air conditioning and plumbing services.

"Houston is an important market for us, and a second location lets us deepen our long-term investment in this region," said Jarrod Brinker, Chief Strategy Officer of Southern Home Services. "Vanderford has earned the trust of its community, and our role is to build on that trust. We're excited to work alongside their team, bringing added resources and support to help them grow, while protecting the local identity and customer relationships at the heart of the business."

The transaction is consistent with Southern's growth strategy of investing in locally operated service companies and providing the infrastructure, training and shared expertise that enable their teams to deliver exceptional service to homeowners.

"Choosing the right partner meant thinking about the people who built this business and the customers who trust us," said Robert Vanderford, owner of Vanderford Air and Plumbing. "Southern's commitment to local brands made them the right fit. I'm excited about what this means for our team as we keep building on what we've created in League City."

About Southern Home Services

Southern Home Services is a house-of-brands home services platform supporting trusted, locally operated HVAC, plumbing, and electrical companies across the South, Midwest, and Mid-Atlantic regions. Since 2016, Southern has provided the leadership, resources, and operational structure that empower its local brands to deliver dependable service, exceptional care, and trusted expertise to homeowners in their communities.

For more information, visit www.southernhomeservices.com/acquisition-program.

MEDIA CONTACT

Desirae Mills, Vice President, Brand Strategy

marketing@southernhomeservices.com

407.676.2860

SOURCE Southern Home Services

Share this article

Nearly nine out of 10 patients experienced a clinical benefit at six months

Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options

GALWAY, Ireland and SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral⢠renal denervation (RDN) system. The study showed statistically significant and clinically meaningful blood pressure reductions at six months, including office, home, and 24-hour ambulatory blood pressure, with no increase in antihypertensive medications. The findings were presented as late-breaking data at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 annual meeting and simultaneously published in Circulation Cardiovascular Interventions.

SPYRAL AFFIRM is a prospective, multicenter, single-arm study designed with the United States (U.S.) Food and Drug Administration (FDA) to provide real-world evidence in patients with uncontrolled hypertension treated in the U.S. across diverse patient populations and clinically relevant subgroups, including women, Black American and Hispanic patients, and patients 65 and older. Six-month results in the U.S. primary endpoint cohort were compared with a prespecified performance goal.

At six months, the data showed:

- Patients treated with Symplicity Spyral had significant reductions in blood pressure compared with baseline:

- Office Systolic Blood Pressure (OSBP): -18.2 ± 22.0 mmHg (p0.0001)

- Home blood pressure: -9.4 ± 13.8 mmHg (p0.0001)

- 24-hour Ambulatory Blood Pressure (ABPM): -9.7 ± 16.8 mmHg (p0.0001)

- Similar blood pressure reductions were demonstrated in women, Black American and Hispanic patients, and patients 65 and older

- There was no increase in antihypertensive medications through six months (3.6 ± 2.0 medications, unchanged from baseline).

- The composite safety endpoint occurred in 2.1% of patients

- Nearly nine out of 10 patients experienced a clinical benefit at six months; a separate pooled analysis replicated this clinical benefit at three years.1

"The blood pressure reductions achieved with RDN in the AFFIRM study are transformative. In fact, they are within the range associated with a greater than 20% reduction in major adverse cardiovascular events, underscoring the clinical significance of these results," said Dr. David Kandzari, chief of Piedmont Heart Institute and Cardiovascular Services and lead principal investigator of the SPYRAL AFFIRM study. "Importantly, the study also demonstrated significant reductions in home blood pressure, offering insight into how patients are responding beyond the clinical setting and in their everyday lives. These findings reinforce the potential benefit of renal denervation in combination with lifestyle changes and medication for patients who continue to struggle with uncontrolled hypertension."

FDA approves Symplicity Spyral RDN system labeling update

Medtronic also announced it has received U.S. FDA approval to update the labeling for the Symplicity Spyral Multi-Electrode Renal Denervation Catheter. The updated labeling includes additional clinical data in patients with isolated systolic hypertension (ISH), chronic kidney disease (CKD) up to stage 3b (eGFR â¥30 mL/min/1.73 m²), and type 2 diabetes, expanding the clinical evidence available to help inform treatment decisions in these patient groups. The indication for use remains unchanged, allowing physicians and patients the full extent of options to manage their hypertension.

"Generating robust clinical evidence across broad and diverse patient populations remains central to our mission of improving outcomes for people living with hypertension," said Lara Barghout, senior vice president and president of Interventional Cardiology Therapies at Medtronic. "Backed by data from SPYRAL AFFIRM and our broader clinical program, this labeling update gives physicians additional information to guide treatment decisions for patients living with hypertension and high cardiovascular risk."

Evidence from the SPYRAL HTN clinical program, including SPYRAL AFFIRM and the Global SYMPLICITY Registry DEFINE, supported the labeling update.

The Symplicity RDN system is approved for commercial use in more than 80 countries around the world.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission â to alleviate pain, restore health, and extend life â unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Kandzari et al, EuroIntervention. 2026;22:e1-e1 published online March 2026. DOI: 10.4244/EIJ-D-26-00161

SOURCE Medtronic plc

Share this article

CHICAGO, Nov. 3, 2026 /PRNewswire/ -- JLL Income Property Trust, an institutionally managed, daily NAV REIT (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX; ZIPIBX; ZIPSAX; ZIPZAX; ZIPDBX) with approximately $7.1 billion in portfolio equity and debt investments, announced the acquisition of West Boston Distribution Center, a premier Class A distribution facility located in Northborough, MA in the western region of the Boston MSA, for a purchase price of approximately $36 million.

The property is a premier Class A distribution facility totaling approximately 54,000 square feet and is 100% leased to a leading distribution tenant, with a recently extended 14-year remaining lease term featuring 2.5% annual escalations. The facility is newly upgraded with 20 additional dock doors, new electric forklifts and an additional maintenance facility totaling 10,000 square feet, and features above market parking with 116 auto stalls and 306 trailer stalls. The property's location offers convenient access to I-495 and I-90, filling a geographic gap for the tenant, providing direct connectivity to the greater Boston transportation network and enabling efficient regional and national distribution.

"The West Boston Distribution Center is an attractive addition to our industrial portfolio," said Allan Swaringen, President and CEO of JLL Income Property Trust. "The warehouse sector has helped drive performance for our core fund, demonstrating resilient fundamentals even as the broader market experienced valuation corrections over the past three years. Looking ahead, our research team anticipates continued rent growth for the sector. With limited supply of these facilities in the Greater Boston market creating strong demand, this acquisition fits our ideal profile for an institutional-quality industrial facility with a high-credit-quality tenant in an infill location."

JLL Income Property Trust's allocation to industrial real estate remains one of its highest conviction property sectors. As of this recent investment, warehouse investments comprise the largest percentage of the total $7.1 billion portfolio at 40%, with $2.7 billion in assets across 66 industrial properties.

JLL Income Property Trust is an institutionally managed, daily NAV REIT that owns a growing portfolio of real estate investments selected by an institutional investment management team and sponsored by one of the world's leading real estate services firms.

For more information on JLL Income Property Trust, please visit our website at www.jllipt.com.

JLL INCOME PROPERTY TRUST, INC. (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX; ZIPIBX; ZIPSAX; ZIPZAX; ZIPDBX),

JLL Income Property Trust, Inc. is a daily NAV REIT that owns and manages a diversified portfolio of high quality, income-producing residential, industrial, grocery-anchored retail, healthcare and office properties located in the United States. JLL Income Property Trust expects to further diversify its real estate portfolio over time, including on a global basis. For more information, visit www.jllipt.com.

ABOUT LASALLE INVESTMENT MANAGEMENT | INVESTING TODAY. FOR TOMORROW.

LaSalle Investment Management, a subsidiary of JLL, is a globally integrated, diverse real estate investment manager. On a global basis, LaSalle manages $88.4 billion of assets in private and public real estate equity and debt investments as of Q2 2026. LaSalle's client base includes public and private pension funds, insurance companies, governments, corporations, endowments and private individuals from across the globe. LaSalle sponsors a diverse range of investment vehicles, including separate accounts, open- and closed-end funds, public securities and entity-level investments.

Forward Looking Statements and Future Results

This press release may contain forward-looking statements with respect to JLL Income Property Trust. Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, research, market analysis, plans or predictions of the future. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. Past performance is not indicative of future results and there can be no assurance that future dividends will be paid.

CONTACTS:

Michael Gelobter

LaSalle Investment Management

Email: Michael.gelobter@lasalle.com

Doug Allen

Dukas Linden Public Relations

Telephone: +1 646 722 6530

Email: JLLIPT@DLPR.com

SOURCE JLL Income Property Trust

Share this article

TOLEDO, Ohio, Nov. 3, 2026 /PRNewswire/ -- Nurenberg, Paris, Heller & McCarthy and Groth & Associates announced that a lawsuit has been filed on behalf of eight individuals against M.C. Tank Transport and its parent company, The Kenan Advantage Group, following the October 20 chemical release in North Toledo (CI2026-04646).

In the complaint, Nurenberg Paris attorneys Jordan Lebovitz, Jeff Heller, and Molly Ebraheim allege that the defendants failed to follow proper safety procedures while transferring the chemical glycidyl methacrylate (GMA), and that heat applied during the transfer set off a chemical reaction that released GMA into the air for nearly 48 hours. The complaint also alleges that Kenan failed to provide adequate safety oversight, training, and procedures despite a history of federal safety citations. GMA is a highly flammable industrial monomer used in plastics, paints, coatings, and adhesives and the World Health Organization's cancer research agency classifies it as a probable human carcinogen.

Victims of the chemical exposure, especially those who were within a close radius to the leak, have been experiencing intense skin and eye irritation, nausea, vomiting, headaches, and sore throats.

"For nearly two days, a chemical poured into the air over North Toledo," said Ebraheim. "Families at home, workers on the job, and travelers just passing through all breathed it in, and now they are forced to live with the fear of what this chemical may do to their health years from now."

The lawsuit seeks to hold M.C. Tank Transport and The Kenan Advantage Group accountable for the harm caused to North Toledo residents, workers, and travelers. Nurenberg Paris and Groth & Associates encourage anyone who believes they were affected by the October 20 chemical release to contact the firms for a free, confidential consultation.

About Nurenberg, Paris, Heller & McCarthy

Nurenberg Paris has been representing injured Ohioans since 1928. Our attorneys are known for their success in cases involving motor vehicle accidents, truck accident, workers' compensation, medical malpractice, birth trauma, wrongful death, defective products and many more. We're proud to have built a law firm that attorneys aspire to work for, and we take pride in our ability to attract top talent because we know that it means delivering exceptional results for our clients.

For more information, visit www.NPHM.com.

SOURCE Nurenberg, Paris, Heller & McCarthy

Share this article